Isturisa 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0015/G 
This was an application for a group of variations. 
27/06/2023 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.1.e - Replacement or addition of a 
amended 
on 
SmPC, Annex II 
and PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except 
batch-release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change in 
the manufacturing process 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.a.1.a - Change or addition of imprints, bossing or 
other markings including replacement, or addition of 
inks used for product marking - Changes in imprints, 
bossing or other markings 
B.II.e.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Tightening of specification limits 
B.II.c.2.b - Change in test procedure for an excipient - 
Deletion of a test procedure if an alternative test 
procedure is already authorised 
B.II.c.2.b - Change in test procedure for an excipient - 
Deletion of a test procedure if an alternative test 
procedure is already authorised 
B.II.c.2.b - Change in test procedure for an excipient - 
Deletion of a test procedure if an alternative test 
procedure is already authorised 
B.II.c.2.b - Change in test procedure for an excipient - 
Deletion of a test procedure if an alternative test 
procedure is already authorised 
Page 2/5 
 
 
 
 
 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IA/0013 
A.7 - Administrative change - Deletion of 
15/12/2022 
n/a 
manufacturing sites 
IA/0012 
A.5.b - Administrative change - Change in the name 
15/12/2022 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/10820
Periodic Safety Update EU Single assessment - 
15/09/2022 
09/11/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202201 
osilodrostat 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10820/202201. 
IA/0010/G 
This was an application for a group of variations. 
22/03/2022 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/10820
Periodic Safety Update EU Single assessment - 
10/02/2022 
n/a 
PRAC Recommendation - maintenance 
/202107 
osilodrostat 
IA/0009 
A.4 - Administrative change - Change in the name 
25/10/2021 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10820
Periodic Safety Update EU Single assessment - 
02/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202101 
osilodrostat 
IAIN/0007/G 
This was an application for a group of variations. 
05/05/2021 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging site 
PSUSA/10820
Periodic Safety Update EU Single assessment - 
11/02/2021 
n/a 
PRAC Recommendation - maintenance 
/202007 
osilodrostat 
IA/0005 
A.4 - Administrative change - Change in the name 
25/01/2021 
n/a 
and/or address of a manufacturer or an ASMF holder 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IAIN/0002/G 
This was an application for a group of variations. 
29/05/2020 
04/06/2021 
Annex II and PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
IA/0003 
B.II.e.6.b - Change in any part of the (primary) 
28/05/2020 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect the 
product information 
T/0001 
Transfer of Marketing Authorisation 
12/03/2020 
01/04/2020 
SmPC, 
Labelling and 
PL 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
